Skip to main content
. 2022 Apr 29;10(5):696. doi: 10.3390/vaccines10050696

Figure 4.

Figure 4

Loss of antibody-protected status based on (A) antibody binding, and (B) viral neutralization in waned participants. (A) All 25 participants demonstrated a loss of anti-RBD binding antibodies; (B) only 13 showed a loss of neutralization potential, signified by an initial non-0 neutralization endpoint titer and an endpoint titer of 0 at the post-waned timepoint. The numbers next to the dots represent the number of overlapping participants with the same neutralizing endpoint titer.